Clinical trial • Phase I • Oncology
JNJ-87801493 for Non-Hodgkin lymphoma
Phase I trial of JNJ-87801493 for Non-Hodgkin lymphoma. 70 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-Hodgkin lymphoma
- Trial Stage
- Phase I
- Drug Modality
- Other|Bispecific antibody
Key dates
- Initial CTIS Submission Date
- 19-10-2023
- First CTIS Authorization Date
- 19-02-2024
Trial design
Phase I trial across 9 sites in Denmark, Spain, France.
- Target Sample Size
- 70
Eligibility
Recruits 70 Vulnerable population selected; no details on consent or assent provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the record.
Recruitment
- Planned Sample Size
- 70
- Recruitment Window Months
- 52
- Consent Approach
- No information provided on informed consent or assent; consent process not specified in the record.
Geography
- Total Number Of Sites
- 9
- Total Number Of Participants
- 70
Denmark
- Earliest CTIS Part Ii Submission Date
- 15-02-2024
- Latest Decision Or Authorization Date
- 16-12-2025
- Processing Time Days
- 670
- Number Of Sites
- 2
- Number Of Participants
- 22
Sites
- Site Name
- Odense University Hospital
- Department Name
- Haematological Research unit HFE-X OUH
- Principal Investigator Name
- Jacob Haaber Christensen
- Principal Investigator Email
- jacob.h.christensen@rsyd.dk
- Contact Person Name
- Jacob Haaber Christensen
- Contact Person Email
- jacob.h.christensen@rsyd.dk
- Site Name
- Rigshospitalet
- Department Name
- Department of Haematology, Clinical Research Unit, 2081
- Principal Investigator Name
- Anna Caroline Riley
- Principal Investigator Email
- anna.caroline.riley@regionh.dk
- Contact Person Name
- Anna Caroline Riley
- Contact Person Email
- anna.caroline.riley@regionh.dk
Spain
- Earliest CTIS Part Ii Submission Date
- 01-02-2024
- Latest Decision Or Authorization Date
- 26-11-2025
- Processing Time Days
- 664
- Number Of Sites
- 4
- Number Of Participants
- 38
Sites
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Hematology
- Principal Investigator Name
- Miguel Angel Canales
- Principal Investigator Email
- macanales@unav.es
- Contact Person Name
- Miguel Angel Canales
- Contact Person Email
- macanales@unav.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Hematology
- Principal Investigator Name
- Daniel Morillo
- Principal Investigator Email
- dmorillo@startmadrid.com
- Contact Person Name
- Daniel Morillo
- Contact Person Email
- dmorillo@startmadrid.com
- Site Name
- Hospital Universitario De Salamanca
- Department Name
- Hematology
- Principal Investigator Name
- Norma Gutierrez
- Principal Investigator Email
- normagu@usal.es
- Contact Person Name
- Norma Gutierrez
- Contact Person Email
- normagu@usal.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Hematology
- Principal Investigator Name
- Pau Abrisqueta
- Principal Investigator Email
- pabrisqueta@vhio.net
- Contact Person Name
- Pau Abrisqueta
- Contact Person Email
- pabrisqueta@vhio.net
France
- Earliest CTIS Part Ii Submission Date
- 06-06-2025
- Latest Decision Or Authorization Date
- 21-11-2025
- Processing Time Days
- 168
- Number Of Sites
- 3
- Number Of Participants
- 10
Sites
- Site Name
- Centre Hospitalier Regional Universitaire De Tours
- Department Name
- Hematology and cell therapy
- Principal Investigator Name
- Emmanuel GYAN
- Principal Investigator Email
- e.gyan@chu-tours.fr
- Contact Person Name
- Emmanuel GYAN
- Contact Person Email
- e.gyan@chu-tours.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Clinical Hematology
- Principal Investigator Name
- Benoit TESSOULIN
- Principal Investigator Email
- benoit.tessoulin@chu-nantes.fr
- Contact Person Name
- Benoit TESSOULIN
- Contact Person Email
- benoit.tessoulin@chu-nantes.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Services des maladies du sang
- Principal Investigator Name
- Franck MORSCHHAUSER
- Principal Investigator Email
- franck.morschhauser@chu-lille.fr
- Contact Person Name
- Franck MORSCHHAUSER
- Contact Person Email
- franck.morschhauser@chu-lille.fr
Sponsor
Primary sponsor
- Full Name
- Janssen - Cilag International
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- JNJ-87801493
- Modality
- Other
- Investigational Product Name
- CD3 T-Cell Engagers
- Modality
- Bispecific antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- Pentixather; Yttrium-90 for Non-Hodgkin lymphoma
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer